REG - Synairgen plc - Director/PDMR Shareholding

SynairgenAnnouncement

28/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220128:nRSb9105Za&default-theme=true

RNS Number : 9105Z  Synairgen plc  28 January 2022

28 January 2022

 

Synairgen plc

 

("Synairgen" or the "Company")

 

Director/PDMR Dealing

 

Southampton, UK - 28 January 2022: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001 (inhaled interferon-beta or IFN-beta) for the
treatment of COVID-19 as potentially the first host-targeted, broad-spectrum
antiviral treatment delivered directly into the lungs, announces that it was
notified on 27 January 2022 that the spouse of Brooke Clarke, Senior Vice
President, Head of Communications and PDMR, had purchased 8,520 ordinary
shares of 1 pence each in the Company ("Ordinary Shares") at an average price
of 189.717p.

 

Following the purchase, the spouse of Brooke Clarke has a total interest over
8,520 Ordinary Shares, representing 0.004 per cent. of the Company's issued
share capital.

 

 

For further information, please contact:

 

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Brooke Clarke, Head of Communications

Tel: +44 (0) 23 8051 2800

 

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: +44 (0) 20 7220 0500

 

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: +44 (0) 20 7260 1000

 

Consilium Strategic Communications (Financial Media and Investor

Relations)

Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

 

MK Strategies, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com

Tel: +1 516 606 6545

 

 

The notification set out below is provided in accordance with the requirements
of the UK Market Abuse Regulation.

 

 1     Details of the person discharging managerial responsibilities/person closely
       associated
 (a)   Name                                                         Thomas Clarke
 2     Reason for the notification
 a)    Position/status                                              Person closely associated with Brooke Clarke, a PDMR
 b)    Initial notification/Amendment                               Initial notification
 3     Details of issuer, emission allowance market participant, auction platform,
       auctioneer or auction monitor
 a)    Name                                                         Synairgen plc
 b)    LEI                                                          213800IMMTOPPDF8HD24
 4     Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted.
 a)    Description of the financial instrument, type of instrument  Ordinary shares of 1p

       Identification code

                                                                    ISIN: GB00B0381Z20
 b)    Nature of the transaction                                    Purchase of shares by spouse
 c)    Price(s) and volume(s)                                       Price(s)                     Volume(s)
                                                                    £1.8974                      7,899

                                                                    £1.8942                      621

 d)    Aggregated information

       -     Aggregated volume                                      8,520 Ordinary Shares

       -     Price                                                  £16,163.86p
 e)    Date of the transaction                                      27 January 2022
 f)    Place of the transaction                                     XLON

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAPFXADLAEFA